Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation

被引:22
|
作者
Palmer, Gaby
Talabot-Ayer, Dominique
Kaya, Guerkan
Gabay, Cem
机构
[1] Univ Hosp Geneva, Div Rheumatol, CH-1211 Geneva 14, Switzerland
[2] Univ Hosp Geneva, Sch Med, Dept Pathol & Immunol, CH-1211 Geneva 14, Switzerland
[3] Univ Hosp Geneva, Dept Dermatol, CH-1211 Geneva 14, Switzerland
关键词
D O I
10.1038/sj.jid.5700803
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The IL-1 system plays a key role in skin physiology and pathology. In this study, we used mutant mice lacking the type I IL-1 receptor (IL-1RI), lacking IL-1 receptor antagonist (IL-1Ra), or overexpressing the human intracellular (ic) IL-1Ra1 isoform, as well as combinations thereof, to dissect the role of the IL-1 system in phorbol 13myristate 12-acetate (PMA)-induced skin inflammation. In wild-type (WT) mice, PMA application induced epidermal thickening and dermal inflammation. Skin IL-1 alpha production and circulating levels of the acute-phase protein serum amyloid A (SAA) were elevated. In mice lacking IL-1RI or overexpressing icIL-1Ra1, PMA induced similar epidermal thickening as in WT mice, but dermal inflammation was partially prevented. Skin IL-1 alpha mRNA expression was similar in PMA-treated IL-1Rl-/- and WT mice, whereas the increase in serum SAA was suppressed in IL-1Rl-/- mice. Interestingly, PMA-induced IL-lar mRNA expression was further enhanced by icIL1Ra1 overexpression in an IL-1RI-dependent manner. Finally, IL-1Ra-/- mice spontaneously displayed skin lesions characterized by high IL-1 beta but not IL-1 alpha, expression. In conclusion, PMA-induced epidermal thickening and skin IL-1 alpha expression were independent of IL-1 signaling, in contrast to dermal inflammation and systemic inflammatory response.
引用
收藏
页码:1938 / 1946
页数:9
相关论文
共 50 条
  • [1] Crystal structure of an IL-1 receptor antagonist peptide complexed with IL-1 receptor type I
    Brandhuber, BJ
    Dripps, DJ
    Edwards, CK
    Vigers, GPA
    FASEB JOURNAL, 2000, 14 (08): : A1394 - A1394
  • [2] The IL-1 system in HIV infection: Peripheral concentrations of IL-1 beta, IL-1 receptor antagonist and soluble IL-1 receptor type II
    Kreuzer, KA
    Dayer, JM
    Rockstroh, JK
    Sauerbruch, T
    Spengler, U
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1997, 109 (01): : 54 - 58
  • [3] The epistatic interrelationships of IL-1, IL-1 receptor antagonist, and the type IIL-1 receptor
    Irikura, VM
    Lagraoui, M
    Hirsh, D
    JOURNAL OF IMMUNOLOGY, 2002, 169 (01): : 393 - 398
  • [4] IL-1β, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders
    Tominaga, K
    Habu, M
    Sukedai, M
    Hirota, Y
    Takahashi, T
    Fukuda, J
    ARCHIVES OF ORAL BIOLOGY, 2004, 49 (06) : 493 - 499
  • [5] Roles of IL-1 and IL-1 receptor antagonist in the immune system
    Horai, R
    Asano, M
    Nakae, S
    Saijo, S
    Sudo, K
    Iwakura, Y
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 380 - 380
  • [6] Interleukin-1α (IL-1α), IL-1β, IL-1 receptor type I, IL-1 receptor antagonist, and TGF-β1 mRNAs in pediatric astrocytomas, ependymomas, and primitive neuroectodermal tumors
    Ilyin, SE
    Gonzalez-Gomez, I
    Gilles, FH
    Plata-Salaman, CR
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1998, 33 (02) : 125 - 137
  • [7] Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II
    Ruggiero, P
    Bossu, P
    Macchia, G
    DelGrosso, E
    Sabbatini, V
    Bertini, R
    Colagrande, A
    Bizzarri, C
    Maurizi, G
    DiCioccio, V
    DAndrea, G
    DiGiulio, A
    Frigerio, F
    Grifantini, R
    Grandi, G
    Tagliabue, A
    Boraschi, D
    JOURNAL OF IMMUNOLOGY, 1997, 158 (08): : 3881 - 3887
  • [8] IL-1 receptor antagonist as an aerosol in inflammation
    Ischenko, Alexander M.
    Nikolaev, Boris P.
    Kotova, Tatiana V.
    Vorobeychikov, Eugeny V.
    Konusova, Velentina G.
    Yakovleva, Ludmila Y.
    JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2007, 20 (04): : 445 - 459
  • [9] MODULATION OF THE IL-1 CYTOKINE NETWORK IN KERATINOCYTES BY INTRACELLULAR IL-1-ALPHA AND IL-1 RECEPTOR ANTAGONIST
    PHILLIPS, WG
    FELDMANN, M
    BREATHNACH, SM
    BRENNAN, FM
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1995, 101 (01): : 177 - 182
  • [10] Differential susceptibility to lethal endotoxaemia in mice deficient in IL-1α, IL-1β or IL-1 receptor type I
    Joosten, Leo A. B.
    van de Veerdonk, Frank L.
    Vonk, Alieke G.
    Boerman, Otto C.
    Keuter, Monique
    Fantuzzi, Giamilla
    Verschueren, Ineke
    van der Poll, Tom
    Dinarello, Charles A.
    Kullberg, Bart Jan
    Van der Meer, Jos W. M.
    Netea, Mihai G.
    APMIS, 2010, 118 (12) : 1000 - 1007